IMMP - Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

• The U.S. Food and Drug Administration (FDA) granted fast track designation to Immutep's ( NASDAQ: IMMP ) eftilagimod alpha (IMP321) in combination with Merck's ( NYSE: MRK ) Keytruda (pembrolizumab) to treat first line non-small cell lung cancer (NSCLC).
• The combo was granted the status for initial treatment of patients with stage 3B/4 NSCLC expressing PD-L1 Tumor Proportion Score ?1%, not amenable to EGFR/ALK based therapy, due to data from a phase 2 trial called TACTI-002/KEYNOTE-798, the company said in an Oct. 4 press release.
• "Efti also offers a chemotherapy-free option for NSCLC patients in need of less toxic and more durable solutions," said Immutep CEO Marc Voigt.
• The efti/Keytruda combo had previously received the FDA's fast track status in April 2021 as a first-line treatment for recurrent or metastatic Head and Neck Squamous Cell Carcinoma.
• IMMP +7.21% to $1.71 premarket Oct. 4

For further details see: